We show for the first time that antibody blockade of PVR or PVRL2 on AML cell lines or primary AML cells or TIGIT blockade on immune cells increases the anti-leukemic effects mediated by PBMCs or purified CD3&lt;sup&gt;+&lt;/sup&gt; cells in vitro.
C0023467
Leukemia, Myelocytic, Acute